{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:06:13Z","timestamp":1792073173305,"version":"4.4.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016062","name":"Metakids Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.pharmthera.2026.109070","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:20:38Z","timestamp":1781911238000},"page":"109070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy"],"prefix":"10.1016","volume":"285","author":[{"given":"Yorrick R.J.","family":"Jaspers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.E.","family":"Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Engelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jimd.12571","article-title":"Sex-specific newborn screening for X-linked adrenoleukodystrophy","volume":"46","author":"Albersen","year":"2023","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2017.07.006","article-title":"Neonatal detection of Aicardi Goutieres syndrome by increased C26:0 lysophosphatidylcholine and interferon signature on newborn screening blood spots","author":"Armangue","year":"2017","journal-title":"Molecular Genetics and Metabolism"},{"issue":"26","key":"10.1016\/j.pharmthera.2026.109070_bb0015","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJM199006283222607","article-title":"Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation","volume":"322","author":"Aubourg","year":"1990","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0020","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3389\/fcell.2020.00499","article-title":"Adrenoleukodystrophy newborn screening in the Netherlands (SCAN study): The X-factor","volume":"8","author":"Barendsen","year":"2020","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109070_bb0025","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/(SICI)1096-8628(19980413)76:5<415::AID-AJMG9>3.0.CO;2-L","article-title":"Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes","volume":"76","author":"Bezman","year":"1998","journal-title":"American Journal of Medical Genetics"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109070_bb0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jamapediatrics.2024.6774","article-title":"Prognostication and biomarker potential of C26:0 Lysophosphatidylcholine in adrenoleukodystrophy","volume":"179","author":"Billington","year":"2025","journal-title":"JAMA Pediatrics"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109070_bb0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/jnr.20248","article-title":"Lysolecithin induces demyelination in vitro in a cerebellar slice culture system","volume":"78","author":"Birgbauer","year":"2004","journal-title":"Journal of Neuroscience Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109070_bb0040","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1006\/mgme.1998.2779","article-title":"Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy","volume":"66","author":"Boehm","year":"1999","journal-title":"Molecular Genetics and Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0885-4505(91)90010-I","article-title":"Clinical variation in X-linked adrenoleukodystrophy: Fatty acid and lipid metabolism in cultured fibroblasts","volume":"45","author":"Boles","year":"1991","journal-title":"Biochemical Medicine and Metabolic Biology"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0050","article-title":"Newborn screening for X-linked adrenoleukodystrophy in Italy: Diagnostic algorithm and disease monitoring","volume":"13","author":"Bonaventura","year":"2022","journal-title":"Frontiers in Neurology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109070_bb0055","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/ijns11040084","article-title":"Newborn screening of X-linked adrenoleukodystrophy in Italy: Clinical and biochemical outcomes from a 4-year pilot study","volume":"11","author":"Bonaventura","year":"2025","journal-title":"International Journal of Neonatal Screening"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109070_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/genes16050590","article-title":"Revisiting the pathogenesis of X-linked adrenoleukodystrophy","volume":"16","author":"Bougn\u00e8res","year":"2025","journal-title":"Genes"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109070_bb0065","doi-asserted-by":"crossref","first-page":"17777","DOI":"10.1021\/acs.jmedchem.1c00948","article-title":"Discovery of novel, orally bioavailable pyrimidine ether-based inhibitors of ELOVL1","volume":"64","author":"Boyd","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109070_bb0070","first-page":"164","article-title":"Adrenoleukodystrophy: Effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids","volume":"151","author":"Brown","year":"1982","journal-title":"The Johns Hopkins Medical Journal"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcis.2026.139886","article-title":"Molecular insights into sphingomyelin membrane alterations induced by very long-chain lysophospholipids","volume":"710","author":"Cabrera","year":"2026","journal-title":"Journal of Colloid and Interface Science"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109070_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076233","article-title":"Lysophosphatidylcholine triggers TLR2- and TLR4-mediated signaling pathways but counteracts LPS-induced NO synthesis in peritoneal macrophages by inhibiting NF-\u03baB translocation and MAPK\/ERK phosphorylation","volume":"8","author":"Carneiro","year":"2013","journal-title":"PLoS One"},{"issue":"5954","key":"10.1016\/j.pharmthera.2026.109070_bb0085","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgmr.2022.100902","article-title":"High incidence of null variants identified from newborn screening of X-linked adrenoleukodystrophy in Taiwan","volume":"32","author":"Chen","year":"2022","journal-title":"Molecular Genetics and Metabolism Reports"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109070_bb0095","doi-asserted-by":"crossref","first-page":"17753","DOI":"10.1021\/acs.jmedchem.1c00944","article-title":"Discovery and optimization of pyrazole amides as inhibitors of ELOVL1","volume":"64","author":"Come","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109070_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/ijns8040051","article-title":"Newborn screening is on a collision course with public health ethics","volume":"8","author":"Currier","year":"2022","journal-title":"International Journal of Neonatal Screening"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109070_bb0105","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/ATVBAHA.123.319937","article-title":"Diacylglycerols and lysophosphatidic acid, enriched on lipoprotein(a), contribute to monocyte inflammation","volume":"44","author":"Dzobo","year":"2024","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109070_bb0110","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.21391","article-title":"Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?","volume":"63","author":"Eichler","year":"2008","journal-title":"Annals of Neurology"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109070_bb0115","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109070_bb0120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamapediatrics.2024.6771","article-title":"Newborn screening for adrenoleukodystrophy","volume":"179","author":"Engelen","year":"2025","journal-title":"JAMA Pediatrics"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109070_bb0125","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1056\/NEJMc0907735","article-title":"Lovastatin in X-linked adrenoleukodystrophy","volume":"362","author":"Engelen","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109070_bb0130","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/brain\/awt361","article-title":"X-linked adrenoleukodystrophy in women: A cross-sectional cohort study","volume":"137","author":"Engelen","year":"2014","journal-title":"Brain"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109070_bb0135","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1212\/WNL.0000000000201374","article-title":"International recommendations for the diagnosis and Management of Patients with Adrenoleukodystrophy: A consensus-based approach","volume":"99","author":"Engelen","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12832","article-title":"Altered lipid profile and reduced neuronal support in human induced pluripotent stem cell-derived astrocytes from adrenoleukodystrophy patients","volume":"48","author":"Ferrer","year":"2025","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"247","key":"10.1016\/j.pharmthera.2026.109070_bb0145","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/adc.46.247.273","article-title":"Adrenocortical atrophy and diffuse cerebral sclerosis","volume":"46","author":"Forsyth","year":"1971","journal-title":"Archives of Disease in Childhood"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109070_bb0150","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/hmg\/ddn085","article-title":"Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy","volume":"17","author":"Fourcade","year":"2008","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109070_bb0155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jimd.12703","article-title":"Increased neurotoxicity of high-density lipoprotein secreted from murine reactive astrocytes deficient in a peroxisomal very-long-chain fatty acid transporter Abcd1","volume":"47","author":"Fujitani","year":"2024","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109070_bb0160","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ana.25085","article-title":"Microglial dysfunction as a key pathological change in adrenomyeloneuropathy","volume":"82","author":"Gong","year":"2017","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0165","doi-asserted-by":"crossref","DOI":"10.1080\/14712598.2022.2124857","article-title":"Treatment of cerebral adrenoleukodystrophy: Allogeneic transplantation and lentiviral gene therapy","author":"Gupta","year":"2022","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109070_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2025.100973","article-title":"Phosphatidylcholine with C26:0 moiety, a precursor of a diagnostic marker for X-ALD, is synthesized by LPLAT10\/LPEAT2","volume":"67","author":"Hama","year":"2026","journal-title":"Journal of Lipid Research"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2026.109070_bb0175","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clinbiochem.2014.10.001","article-title":"The stability of hexacosanoyl lysophosphatidylcholine in dried-blood spot quality control materials for X-linked adrenoleukodystrophy newborn screening","volume":"48","author":"Haynes","year":"2015","journal-title":"Clinical Biochemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.clinbiochem.2015.09.011","article-title":"Simultaneous quantitation of hexacosanoyl lysophosphatidylcholine, amino acids, acylcarnitines, and succinylacetone during FIA-ESI-MS\/MS analysis of dried blood spot extracts for newborn screening","volume":"49","author":"Haynes","year":"2016","journal-title":"Clinical Biochemistry"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109070_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113248","article-title":"Elovl1 inhibition reduced very long chain fatty acids in a mouse model of adrenoleukodystrophy","volume":"28","author":"Huang","year":"2025","journal-title":"IScience"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2026.109070_bb0190","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ymgme.2006.05.001","article-title":"Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: Preliminary findings","volume":"89","author":"Hubbard","year":"2006","journal-title":"Molecular Genetics and Metabolism"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109070_bb0195","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2009.03.010","article-title":"Newborn screening for X-linked adrenoleukodystrophy (X-ALD): Validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS\/MS) method","volume":"97","author":"Hubbard","year":"2009","journal-title":"Molecular Genetics and Metabolism"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109070_bb0200","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ymgme.2017.10.012","article-title":"Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy","volume":"122","author":"Huffnagel","year":"2017","journal-title":"Molecular Genetics and Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0205","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13023-019-1008-6","article-title":"Disease progression in women with X-linked adrenoleukodystrophy is slow","volume":"14","author":"Huffnagel","year":"2019","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0210","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1210\/jc.2018-01307","article-title":"The natural history of adrenal insufficiency in X-linked adrenoleukodystrophy: An international collaboration","volume":"104","author":"Huffnagel","year":"2019","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109070_bb0215","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1471-4159.1976.tb04461.x-i1","article-title":"Fatty acid abnormality in adrenoleukodystrophy","volume":"26","author":"Igarashi","year":"1976","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0220","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3389\/fcell.2020.00690","article-title":"Comparison of the diagnostic performance of C26:0-Lysophosphatidylcholine and very long-chain fatty acids analysis for peroxisomal disorders","volume":"8","author":"Jaspers","year":"2020","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109070_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100567","article-title":"Four-dimensional lipidomics profiling in X-linked adrenoleukodystrophy using trapped ion mobility mass spectrometry","volume":"65","author":"Jaspers","year":"2024","journal-title":"Journal of Lipid Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0230","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s43856-024-00605-9","article-title":"Lipidomic biomarkers in plasma correlate with disease severity in adrenoleukodystrophy","volume":"4","author":"Jaspers","year":"2024","journal-title":"Communications Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109070_bb0235","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/24.6.59773","article-title":"Histochemical characteristics of the striated inclusions of adrenoleukodystrophy","volume":"24","author":"Johnson","year":"1976","journal-title":"The Journal of Histochemistry and Cytochemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109070_bb0240","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/humu.1227","article-title":"ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: Role in diagnosis and clinical correlations","volume":"18","author":"Kemp","year":"2001","journal-title":"Human Mutation"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2026.109070_bb0245","article-title":"VUS: Variant of uncertain significance or very unclear situation?","volume":"140","author":"Kemp","year":"2023","journal-title":"Molecular Genetics and Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0250","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/gim.2016.68","article-title":"Newborn screening for X-linked adrenoleukodystrophy: Evidence summary and advisory committee recommendation","volume":"19","author":"Kemper","year":"2017","journal-title":"Genetics in Medicine"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12389","article-title":"Targeted metabolomics revealed changes in phospholipids during the development of neuroinflammation in Abcd1tm1Kds mice and X-linked adrenoleukodystrophy patients","author":"Kettwig","year":"2021","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0260","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0006-291X(80)91182-1","article-title":"Adrenoleukodystrophy: Evidence that abnormal very long chain fatty acids of brain cholesterol esters are of exogenous origin","volume":"96","author":"Kishimoto","year":"1980","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109070_bb0265","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10545-017-0064-0","article-title":"Evaluation of C26:0-lysophosphatidylcholine and C26:0-carnitine as diagnostic markers for Zellweger spectrum disorders","volume":"40","author":"Klouwer","year":"2017","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109070_bb0270","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.3390\/ijms21124501","article-title":"An updated review of pro- and anti-inflammatory properties of plasma Lysophosphatidylcholines in the vascular system","volume":"21","author":"Knuplez","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109070_bb0275","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ymgme.2012.07.015","article-title":"Peanut consumption increases levels of plasma very long chain fatty acids in humans","volume":"107","author":"Lam","year":"2012","journal-title":"Molecular Genetics and Metabolism"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109070_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20051149","article-title":"An updated review of Lysophosphatidylcholine metabolism in human diseases","volume":"20","author":"Law","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0285","article-title":"Nervonic acid supplementation mitigates disease severity biomarkers in adrenoleukodystrophy","volume":"e00890","author":"Li","year":"2026","journal-title":"Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109070_bb0290","doi-asserted-by":"crossref","first-page":"e1698","DOI":"10.1212\/WNL.0000000000007294","article-title":"MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy","volume":"92","author":"Liberato","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117443","article-title":"The mechanisms of lysophosphatidylcholine in the development of diseases","volume":"247","author":"Liu","year":"2020","journal-title":"Life Sciences"},{"issue":"16","key":"10.1016\/j.pharmthera.2026.109070_bb0300","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1093\/hmg\/ddt186","article-title":"Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy","volume":"22","author":"Lopez-Erauskin","year":"2013","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.omta.2026.201702","article-title":"CSF and plasma neuro-biomarker dynamics after gene therapy for cerebral adrenoleukodystrophy","volume":"34","author":"Lund","year":"2026","journal-title":"Molecular Therapy. Advances"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109070_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70157","article-title":"The Grey zone project: Risk-based classification of ABCD1 variants in X-linked adrenoleukodystrophy","volume":"49","author":"Lund","year":"2026","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109070_bb0315","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1085\/jgp.104.4.645","article-title":"Lysophospholipids modulate channel function by altering the mechanical properties of lipid bilayers","volume":"104","author":"Lundbaek","year":"1994","journal-title":"The Journal of General Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109070_bb0320","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/cells11020283","article-title":"Structure and function of the ABCD1 variant database: 20 years, 940 pathogenic variants, and 3400 cases of adrenoleukodystrophy","volume":"11","author":"Mallack","year":"2022","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109070_bb0325","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0022-2275(20)30466-1","article-title":"Characterization of the lipolytic activity of endothelial lipase","volume":"43","author":"McCoy","year":"2002","journal-title":"Journal of Lipid Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109070_bb0330","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1353\/dem.2007.0038","article-title":"What a drop can do: Dried blood spots as a minimally invasive method for integrating biomarkers into population-based research","volume":"44","author":"McDade","year":"2007","journal-title":"Demography"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109070_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100516","article-title":"Plasma C24:0- and C26:0-lysophosphatidylcholines are reliable biomarkers for the diagnosis of peroxisomal \u03b2-oxidation disorders","volume":"65","author":"Morales-Romero","year":"2024","journal-title":"Journal of Lipid Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109070_bb0340","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ana.410160603","article-title":"Adrenoleukodystrophy: Survey of 303 cases: Biochemistry, diagnosis, and therapy","volume":"16","author":"Moser","year":"1984","journal-title":"Annals of Neurology"},{"issue":"4\u20135","key":"10.1016\/j.pharmthera.2026.109070_bb0345","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000112170","article-title":"Clinical aspects of adrenoleukodystrophy and adrenomyeloneuropathy","volume":"13","author":"Moser","year":"1991","journal-title":"Developmental Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0350","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/1531-8249(199901)45:1<100::AID-ART16>3.0.CO;2-U","article-title":"Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls","volume":"45","author":"Moser","year":"1999","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0355","series-title":"The metabolic and molecular bases of inherited disease","first-page":"3257","article-title":"X-Linked Adrenoleukodystrophy","author":"Moser","year":"2001"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109070_bb0360","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/ijns2040015","article-title":"Newborn screening for X-linked adrenoleukodystrophy","volume":"2","author":"Moser","year":"2016","journal-title":"International Journal of Neonatal Screening"},{"issue":"6414","key":"10.1016\/j.pharmthera.2026.109070_bb0365","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/361726a0","article-title":"Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters","volume":"361","author":"Mosser","year":"1993","journal-title":"Nature"},{"issue":"7501","key":"10.1016\/j.pharmthera.2026.109070_bb0370","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nature13241","article-title":"Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid","volume":"509","author":"Nguyen","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0375","doi-asserted-by":"crossref","DOI":"10.1002\/ajmg.a.63144","article-title":"Neonatal lupus is a novel cause of positive newborn screening for X-linked adrenoleukodystrophy","author":"Niehaus","year":"2023","journal-title":"American Journal of Medical Genetics. Part A"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109070_bb0380","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/emmm.201000061","article-title":"The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy","volume":"2","author":"Ofman","year":"2010","journal-title":"EMBO Molecular Medicine"},{"issue":"43","key":"10.1016\/j.pharmthera.2026.109070_bb0385","doi-asserted-by":"crossref","first-page":"18439","DOI":"10.1073\/pnas.1005572107","article-title":"ELOVL1 production of C24 acyl-CoAs is linked to C24 sphingolipid synthesis","volume":"107","author":"Ohno","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109070_bb0390","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/glia.23245","article-title":"Mechanisms of lysophosphatidylcholine-induced demyelination: A primary lipid disrupting myelinopathy","volume":"66","author":"Plemel","year":"2018","journal-title":"Glia"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109070_bb0395","first-page":"481","article-title":"Adreno-leukodystrophy (sex-linked Schilder\u2019s disease). A pathogenetic hypothesis based on ultrastructural lesions in adrenal cortex, peripheral nerve and testis","volume":"76","author":"Powers","year":"1974","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118569","article-title":"Phospholipid-derived lysophospholipids in (patho)physiology","volume":"398","author":"Prabutzki","year":"2024","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109070_bb0405","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142500","article-title":"Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy","volume":"131","author":"Raas","year":"2021","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0410","doi-asserted-by":"crossref","first-page":"15093","DOI":"10.1038\/s41598-020-71248-8","article-title":"Defining diagnostic cutoffs in neurological patients for serum very long chain fatty acids (VLCFA) in genetically confirmed X-adrenoleukodystrophy","volume":"10","author":"Rattay","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0415","article-title":"Insights from Minnesota on Newborn screening for adrenoleukodystrophy: A 5-year update","volume":"e63995","author":"Rayannavar","year":"2025","journal-title":"American Journal of Medical Genetics. Part A"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109070_bb0420","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbmt.2018.09.036","article-title":"Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation","volume":"25","author":"Raymond","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109070_bb0425","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1210\/jc.2018-00920","article-title":"Adrenoleukodystrophy: Guidance for adrenal surveillance in males identified by Newborn screen","volume":"103","author":"Regelmann","year":"2018","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109070_bb0430","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.atherosclerosis.2010.11.007","article-title":"Endothelial lipase (EL) and EL-generated lysophosphatidylcholines promote IL-8 expression in endothelial cells","volume":"214","author":"Riederer","year":"2011","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109070_bb0435","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1212\/WNL.39.11.1415","article-title":"Dietary erucic acid therapy for X-linked adrenoleukodystrophy","volume":"39","author":"Rizzo","year":"1989","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109070_bb0440","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2011.11.195","article-title":"Combined extraction of acyl carnitines and 26:0 lysophosphatidylcholine from dried blood spots: Prospective newborn screening for X-linked adrenoleukodystrophy","volume":"105","author":"Sandlers","year":"2012","journal-title":"Molecular Genetics and Metabolism"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109070_bb0445","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archneur.1975.00490510033001","article-title":"Adrenoleukodystrophy. A clinical and pathological study of 17 cases","volume":"32","author":"Schaumburg","year":"1975","journal-title":"Archives of Neurology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109070_bb0450","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/ijns7030058","article-title":"Advanced diagnostic system and introduction of Newborn screening of adrenoleukodystrophy and peroxisomal disorders in Japan","volume":"7","author":"Shimozawa","year":"2021","journal-title":"International Journal of Neonatal Screening"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109070_bb0455","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0006-291X(81)80142-8","article-title":"Adrenoleukodystrophy: Impaired oxidation of long chain fatty acids in cultured skin fibroblasts an adrenal cortex","volume":"102","author":"Singh","year":"1981","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109070_bb0460","doi-asserted-by":"crossref","DOI":"10.3390\/nu16193341","article-title":"Nutritional Counseling and Mediterranean diet in adrenoleukodystrophy: A real-life experience","volume":"16","author":"Spreghini","year":"2024","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0465","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0005-2760(92)90261-S","article-title":"Altered positional specificity of human plasma lecithin-cholesterol acyltransferase in the presence of sn-2 arachidonoyl phosphatidyl cholines. Mechanism of formation of saturated cholesteryl esters","volume":"1128","author":"Subbaiah","year":"1992","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2020.101068","article-title":"Emerging roles of lysophospholipids in health and disease","volume":"80","author":"Tan","year":"2020","journal-title":"Progress in Lipid Research"},{"issue":"5 Pt 1","key":"10.1016\/j.pharmthera.2026.109070_bb0475","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0022-3476(06)80013-2","article-title":"Increased very long chain fatty acids in patients on a ketogenic diet: A cause of diagnostic confusion","volume":"122","author":"Theda","year":"1993","journal-title":"The Journal of Pediatrics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0480","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ymgme.2013.10.019","article-title":"Newborn screening for X-linked adrenoleukodystrophy: Further evidence high throughput screening is feasible","volume":"111","author":"Theda","year":"2014","journal-title":"Molecular Genetics and Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109070_bb0485","series-title":"American journal of medical genetics. Part A","article-title":"Aicardi-Gouti\u00e8res syndrome may present with positive newborn screen for X-linked adrenoleukodystrophy","author":"Tise","year":"2021"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0490","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ymgme.2014.11.013","article-title":"Streamlined determination of lysophosphatidylcholines in dried blood spots for newborn screening of X-linked adrenoleukodystrophy","volume":"114","author":"Turgeon","year":"2015","journal-title":"Molecular Genetics and Metabolism"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109070_bb0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154597","article-title":"C26:0-carnitine is a new biomarker for X-linked adrenoleukodystrophy in mice and man","volume":"11","author":"van de Beek","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109070_bb0500","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.bbadis.2017.06.003","article-title":"Lipid-induced endoplasmic reticulum stress in X-linked adrenoleukodystrophy","volume":"1863","author":"van de Beek","year":"2017","journal-title":"Biochimica et Biophysica Acta"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0505","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbadis.2003.10.004","article-title":"Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy","volume":"1688","author":"Vargas","year":"2004","journal-title":"Biochimica et Biophysica Acta"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109070_bb0510","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ymgme.2015.02.002","article-title":"Newborn screening for X-linked adrenoleukodystrophy in New York state: Diagnostic protocol, surveillance protocol and treatment guidelines","volume":"114","author":"Vogel","year":"2015","journal-title":"Molecular Genetics and Metabolism"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109070_bb0515","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1073\/pnas.1217611110","article-title":"Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains","volume":"110","author":"Volmer","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109070_bb0520","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0378-4347(98)00186-8","article-title":"Rapid stable isotope dilution analysis of very-long-chain fatty acids, pristanic acid and phytanic acid using gas chromatography-electron impact mass spectrometry","volume":"713","author":"Vreken","year":"1998","journal-title":"Journal of Chromatography. B, Biomedical Sciences and Applications"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109070_bb0525","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.biochem.74.082803.133329","article-title":"Biochemistry of mammalian peroxisomes revisited","volume":"75","author":"Wanders","year":"2006","journal-title":"Annual Review of Biochemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109070_bb0530","first-page":"272","article-title":"Peroxisomes, lipid metabolism and lipotoxicity. Biochimica et Biophysica acta (BBA) - molecular and cell biology of","volume":"1801","author":"Wanders","year":"2010","journal-title":"Lipids"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109070_bb0535","doi-asserted-by":"crossref","DOI":"10.3390\/ijns9030051","article-title":"Attitudes of patients with adrenoleukodystrophy toward sex-specific Newborn screening","volume":"9","author":"Yska","year":"2023","journal-title":"International Journal of Neonatal Screening"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109070_bb0540","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaf371","article-title":"Myelin-water imaging and multi-shell diffusion-weighted imaging in adults with adrenoleukodystrophy","volume":"7","author":"Yska","year":"2025","journal-title":"Brain Communications"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826000975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826000975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:23:11Z","timestamp":1783603391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826000975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":108,"alternative-id":["S0163725826000975"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109070","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109070"}}